CD274 and neoplasm: The clinical utility of PD-L1 testing varies greatly between cancer types and treatment settings [87], and for aHCC, further high-quality RCTs evaluating PD-L1 expression are needed to determine whether the assessment of tumour PD-L1 expression can impact on clinical management.